Outlook Therapeutics, Inc.
OTLK- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649989
In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.
Holders of 5% or more of OTLK
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Outlook Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| GMS Ventures & Investments | 13D/A | 50.30%29.0M shares | +8.70 ppfrom 41.60% | Jan 22, 20253 filings | May 28, 2025 | SEC |
| Sphera Funds Management Ltd. | 13G/A | 7.49%2.57M shares | +2.28 ppfrom 5.21% | Mar 3, 20252 filings | Apr 10, 2025 | SEC |
| Tang Capital Partners LP | 13G/A | 6.40%1.68M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Outlook Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Oct 21, 20259:00 AM ET | Empery Asset Management, LPand 2 others | 13G/A | 4.99%2.33M shares | −2.58 ppfrom 7.57%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20255:15 PM ET | Great Point Partners LLCand 2 others | 13G/A | 4.99%2.22M shares | −1.38 ppfrom 6.37%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20254:15 PM ET | Tang Capital Management LLCand 5 others | 13G/A | 3.40%1.50M shares | −2.20 ppfrom 5.60%Below 5% | Jun 30, 2025 | SEC |
| Jul 31, 20254:35 PM ET | Empery Asset Management, LPand 2 others | 13G | 7.57%3.20M shares | New | Jun 30, 2025 | SEC |
| May 28, 20255:24 PM ET | GMS Ventures & Investmentsand 1 other | 13D/A | 50.30%29.0M shares | +8.70 ppfrom 41.60% | May 27, 2025 | SEC |
| May 15, 20254:47 PM ET | Great Point Partners LLCand 2 others | 13G/A | 6.37%2.22M shares | −1.81 ppfrom 8.18% | Mar 31, 2025 | SEC |
| May 15, 20254:15 PM ET | Tang Capital Management LLCand 5 others | 13G/A | 5.60%1.90M shares | – | Mar 31, 2025 | SEC |
| Apr 10, 20255:28 PM ET | Sphera Funds Management Ltd.and 2 others | 13G/A | 7.49%2.57M shares | +2.28 ppfrom 5.21% | Apr 10, 2025 | SEC |
| Mar 12, 20259:11 PM ET | GMS Ventures & Investmentsand 1 other | 13D/A | 41.60%16.2M shares | +3.00 ppfrom 38.60% | Mar 11, 2025 | SEC |
| Mar 3, 20253:58 PM ET | Sphera Funds Management Ltd.and 2 others | 13G | 5.21%1.71M shares | New | Jan 17, 2025 | SEC |
| Feb 14, 20254:38 PM ET | Great Point Partners LLCand 2 others | 13G/A | 8.18%2.22M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20254:00 PM ET | Tang Capital Partners LPand 4 others | 13G/A | 6.40%1.68M shares | – | Dec 31, 2024 | SEC |
| Jan 22, 20254:17 PM ET | GMS Ventures & Investmentsand 1 other | 13D/A | 38.60%12.7M shares | – | Jan 17, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Outlook Therapeutics, Inc. shares.
No Form 144 notices for Outlook Therapeutics, Inc. are on file.